Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Senti Biosciences (SNTI) EBIT Margin (2021 - 2023)

Senti Biosciences has reported EBIT Margin over the past 3 years, most recently at 12981.07% for Q3 2023.

  • For Q3 2023, EBIT Margin fell 1200824.0% year-over-year to 12981.07%; the TTM value through Jun 2024 reached 27287.28%, down 2541663.0%, while the annual FY2025 figure was 312631.82%, N/A changed from the prior year.
  • EBIT Margin for Q3 2023 was 12981.07% at Senti Biosciences, down from 2210.77% in the prior quarter.
  • Over five years, EBIT Margin peaked at 8792.67% in Q4 2022 and troughed at 12981.07% in Q3 2023.
  • A 3-year average of 1424.5% and a median of 1110.67% in 2021 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: skyrocketed 928017bps in 2022 and later crashed -1200824bps in 2023.
  • Year by year, EBIT Margin stood at 487.5% in 2021, then soared by 1904bps to 8792.67% in 2022, then tumbled by -248bps to 12981.07% in 2023.
  • Business Quant data shows EBIT Margin for SNTI at 12981.07% in Q3 2023, 2210.77% in Q2 2023, and 1163.61% in Q1 2023.